Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 25, 2026

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

View original at globenewswire.com
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Me…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Despite new therapeutic options, there is significant need for innovative, well-tolerated therapies with faster time to onset of molecular response leading to deeper responses and better disease control for chronic myeloid leukemia

    60% confidence

  • Based on early clinical evidence, TERN-701, a novel allosteric BCR::ABL1 inhibitor, may have the potential to provide a meaningfully differentiated option for certain patients living with CML

    60% confidence

  • TERN-701 has shown promising activity in clinical trials to date, with encouraging rates of major molecular response and deep molecular response observed by week 24, including responses in patients with high disease burden who previously received multiple lines of therapy

    60% confidence

  • The majority of treatment-emergent adverse events for TERN-701 were reported as low grade with a low incidence of severe adverse events and discontinuations, with no clinically meaningful changes in blood pressure and low rates of lipase elevation

    60% confidence

  • The acquisition of Terns builds on Merck's growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia

    60% confidence

  • By working together with Merck, Terns will advance TERN-701, leveraging the deep expertise and significant resources at Merck, a global biopharmaceutical leader with a proven track record of delivering cancer breakthroughs

    60% confidence

  • This transaction further diversifies and strengthens Merck's position in oncology as the company continues to look for opportunities to broaden its portfolio into other therapeutic areas

    60% confidence

Cited in these Via News reports